FDA approves the third anti-TB drug in more than 40 years after the compound showed significantly higher success rates in patients with multi drug-resistant and extensively drug-resistant TB.
CSSi LifeSciences and BioMARC have announced a strategic partnership to provide 'fully cohesive product development and support' for vaccine and biologic development.
As the death toll from MERS in South Korea edged to two dozen scientists there say the outbreak is different from in Saudi Arabia and also from its the related virus SARS.
Recipharm says it has not decided whether to go public and list on the Swedish stock market after reports suggested it is preparing to join the exchange.
PPD has expanded its central lab testing services at its Brussels and Singapore labs and will offer additional services in microbiology, peripheral blood mononuclear cell and molecular pathology services.
GlaxoSmithKline (GSK) thinks that drugs based on boron, rather than
carbon, could side-step the issue of resistance in anti-bacterial
and anti-viral therapy - and is willing to bet billions on it.
AstraZeneca (AZ) has continued its pipeline consolidation by
investing a further $100m (€77m) in its Boston research centre,
which focuses on treatments for infectious diseases and cancer.
A new computational program has been developed by US researchers
that uses computational systems biology to better understand the
biochemical networks that regulate the interactions between
infectious organisms and the human or animal...
Nanogen introduces its latest enterovirus reagent, which employs
hybridisation technology designed to detect
enteroviruses-associated sequences. Enterovirus infections cause a
wide spectrum of diseases and are the most common cause...
Researchers in the UK think that knowledge of 'movement routes' is
the key to predicting patterns of spread of infectious diseases in
humans, which would enable scientists to administer effective drug
therapies that are...
Graffinity, announced today that it has entered into its second
research collaboration with Mutabilis, which aims to discover novel
therapeutics for infectious diseases, building on 2003's
collaboration focusing on another anti-infective...
Scientists have devised a way of using live' bacteria in yoghurt to
deliver therapeutics that can prevent HIV infection, potentially
opening up a new avenue for probiotic dairy to play a more
prominent role in drug delivery.
Norwegian biotechnology firm, Genpoint, is running trials of new
DNA tests for tuberculosis (TB) in which its novel DNA method aims
to cut diagnosis time, cheaper and quicker without an increase of
personnel in the health care sector.
STMicroelectronics and Mobidiag unveil a new technology that
enables rapid bacterial diagnosis. The new lab-on-a-chip
application allows a more accurate detection of infectious diseases
that will lead to better treatment choices.
A new laboratory method for quickly detecting active anthrax
proteins within an infected blood sample at extremely low levels
has been developed by researchers, who believe the system will
become useful in developing reliable ways...
The Foundation for Innovative New Diagnostics (FIND) and Eiken
Chemicals have announced a collaboration to develop a rapid and
simple test for the detection of active tuberculosis (TB), a
disease that has infected close to a third...
Scientists have discovered the antimonial drugs used to treat
Leishmaniasis focus on the same drug targets as those drugs used to
treat sleeping sickness and Chagas disease, raising the possibility
of a multi-functional drug that...
Human clinical trials involving an Ebola vaccine took a step closer
after Dutch biotechnology firm Crucell announced a single dose of
its Ebola vaccine had successfully protected monkeys during trial
tests.
There are fears that a renewed epidemic of severe acute respiratory
syndrome (SARS) could occur in 2004, after initial tests on a
patient with symptoms associated with the disease suggested that
the causative agent was the SARS coronavirus...
Denmark-based vaccines company Bavarian Nordic is investing DK 250
million (€33.6m) in a production facility that will be the largest
of its kind in Europe, producing up to 120 million vaccine doses a
year.
